沙特阿拉伯骨质疏松症药物市场 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

沙特阿拉伯骨质疏松症药物市场 – 行业趋势和 2029 年预测

  • Pharmaceutical
  • Published Report
  • Mar 2022
  • Country Level
  • 350 页面
  • 桌子數: 20
  • 图号: 54

>沙特阿拉伯骨质疏松症药物市场,按类型(原发性骨质疏松症和继发性骨质疏松症)、药物(双膦酸盐、单克隆抗体、激素疗法和其他)、药物类型(品牌和通用)、给药途径(注射、口服和其他)、性别(女性和男性)、年龄组(老年病、成人和儿科)、最终用户(医院、专科诊所、家庭护理和其他)、分销渠道(直接招标、零售销售和其他)行业趋势和预测到 2029 年。

沙特阿拉伯骨质疏松症药物市场分析与洞察

根据国际骨质疏松基金会 (IOF) 的说法,“骨质疏松症,即骨质疏松,是一种骨骼质量和密度下降的疾病。随着骨骼变得越来越脆弱和多孔,骨折的风险大大增加。骨质流失是逐渐发生的,而且悄无声息。通常在第一次骨折发生之前没有任何症状。

随着年龄的增长,一些骨细胞开始溶解骨基质,这个过程称为吸收,而新骨细胞沉积类骨质,这个过程称为形成。这个过程称为重塑。对于骨质疏松症患者,骨质流失的速度超过了新骨的生长速度。骨骼变得脆弱、多孔且容易骨折。虽然骨质疏松性骨折也可能发生在其他骨骼中,但最常见的是腕骨、脊柱或髋骨。

市场上有不同类型的骨质疏松症药物。双膦酸盐通常是治疗骨质疏松症的首选。这些药物包括利塞膦酸盐 (Actonel),每周或每月服用一次,阿仑膦酸盐 (Fosamax),每周服用一次,唑来膦酸 (Reclast),每年静脉输液一次,伊班膦酸盐 (Boniva),每月服用一次或每季度静脉 (IV) 输液一次。

Data Bridge Market Research分析,沙特阿拉伯骨质疏松症药物市场在2022年至2029年的预测期内将以2.9%的复合年增长率增长。

报告指标

细节

预测期

2022 至 2029 年

基准年

2021

历史岁月

2020(可定制至 2019 - 2014)

定量单位

收入(百万美元),定价(美元)

涵盖的领域

类型(原发性骨质疏松症和继发性骨质疏松症)、药物(双膦酸盐、单克隆抗体、激素疗法和其他)、药物类型(品牌和仿制药)、给药途径(注射、口服和其他)、性别(女性和男性)、年龄组(老年病、成人和儿科)、最终用户(医院、专科诊所、家庭护理和其他)、分销渠道(直接招标、零售和其他)

覆盖国家

沙特阿拉伯

涵盖的市场参与者

礼来公司(美国)、诺华公司(瑞士)、安进公司(美国)、塔布克制药公司(沙特阿拉伯)、SPIMACO(沙特阿拉伯)、Hikma Pharmaceuticals PLC(约旦)、辉瑞公司(美国)、默克公司(德国)、Apotex 公司(加拿大)、ABIOGEN PHARMA SpA(意大利)、Sudair Pharma(沙特阿拉伯)、tadawipharma.(沙特阿拉伯)、Fresenius SE & Co. KGaA(德国)、Hayat Pharmaceutical Industries Co. PLC(约旦)和 SAJA Pharmaceuticals(沙特阿拉伯)

骨质疏松症药物市场动态

驱动程序

  • 骨质疏松症患病率上升

骨质疏松症是一种骨骼疾病,其发病原因是骨矿物质密度和骨量减少,或骨骼质量或结构发生变化。骨质疏松症可能会因骨骼强度下降而增加骨折的风险,导致骨折。

例如,

  • 根据国际骨质疏松基金会的数据,中东地区低骨量患病率高于西方国家。虽然骨质疏松症会影响男性和女性,但女性患骨质疏松症的可能性高于男性
  • 老年人口增加

随着老年人口的增加,骨质疏松症和骨骼疾病在老年人口中也日益增多。老年人口将需要骨科中心,这将增加对骨质疏松症治疗的需求,因此有望成为沙特阿拉伯骨质疏松症药物市场增长的驱动力。

机会

  • 政府举措

骨质疏松症通常被称为“沉默的疾病”,因为骨质流失是无痛且渐进的,并且通常没有任何症状表明一个人正在患上骨质疏松症。因此,政府正在全国范围内采取主动措施,对疾病进行早期筛查、诊断和治疗。因此,这为未来几年的市场增长提供了机会。

限制/挑战

然而,骨质疏松药物的副作用和高昂的治疗费用将阻碍沙特阿拉伯骨质疏松药物市场的增长。此外,医疗保健系统重组进展缓慢将在上述预测期内进一步挑战市场。

本骨质疏松药物市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响,分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关实验室用品市场的更多信息,请联系 Data Bridge Market Research 获取分析师简报,我们的团队将帮助您做出明智的市场决策,实现市场增长。

患者流行病学分析

Osteoporosis is a disease of bone which progresses due to the less bone mineral density and bone mass or due to some variation in the quality or structure of bone. According to the Ministry of Health of Saudi Arabia, in 2018, the prevalence of osteoporosis was 37% in the population above the age of 50 years.

According to the international journal of research in medical sciences, in 2014, 82% of Saudi women patients had vitamin D deficiency. Only 21% of women were exposed to sunlight, 58% of the women had low BMD, out of which 18% with osteoporosis and 40% with osteopenia.

Osteoporosis drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohot multivariate statistical model for forecasting the market in growth period.

Post COVID-19 Impact on Lab Supplies Market

The COVID-19 has negatively affected the market. Lockdowns and isolations during pandemic complicates the disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.

Recent Development

  • In September 2021, Hikma Pharmaceuticals PLC announced that it has agreed to acquire Custopharm Inc. to grow the injectable and generic business segments of the company. Custopharm has received 13 US FDA approvals, with four first-to-market Abbreviated New Drug Application (ANDA) approvals - including one with Competitive Generic Therapy (CGT) designation - and one novel 505(b)(2) NDA approval.  This acquisition helped the company to increase its product portfolio and to further grow the overall revenue of the company.

沙特阿拉伯骨质疏松症药物市场

Saudi Arabia Osteoporosis Drugs Market Scope

The osteoporosis drugs market is categorized into eight notable segments based on type, drugs, drugs type, route of administration, gender, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Primary Osteoporosis
  • Secondary Osteoporosis.

On the basis of type, Saudi Arabia osteoporosis drugs market is segmented into primary osteoporosis and secondary osteoporosis.

Drugs

  • Bisphosphonates
  • Monoclonal Antibodies
  • Hormone Therapy
  • Others

On the basis of drugs, Saudi Arabia osteoporosis drugs market is segmented into bisphosphonates, monoclonal antibodies, hormone therapy and others.

Drugs Type

  • Branded
  • Generic

On the basis of drugs type, Saudi Arabia osteoporosis drugs market is segmented into branded and generic.

Route of Administration

  • Injectable
  • Oral
  • Others

根据给药途径,沙特阿拉伯骨质疏松症药物市场分为注射剂、口服剂和其他剂型。

性别

  • 女性
  • 男性

根据性别,沙特阿拉伯骨质疏松症药物市场分为女性和男性。

年龄组

  • 老年病学
  • 成年人
  • 儿科

根据年龄组,沙特阿拉伯骨质疏松症药物市场分为老年病学、成人病学和儿科病学。

最终用户

  • 医院
  • 专科诊所
  • 家庭护理
  • 其他的

根据最终用户,沙特阿拉伯骨质疏松症药物市场分为医院、专科诊所、家庭护理和其他。

分销渠道

  • 直接招标
  • 零售销售
  • 其他的

根据分销渠道,沙特阿拉伯骨质疏松药物市场分为直接招标、零售销售和其他。

管道分析

骨质疏松药物市场的管道分析包括各种管道疗法,例如伊班膦酸盐、利塞膦酸钠、伊班膦酸盐(Bonviva/Boniva)、雷奈酸锶。F. Hoffman-La Roche Ltd、Sanofi、Nycomed、Elly Lilly and Company 和 Nordic Biosciences A/S 等公司都参与了改善骨质疏松症治疗的潜在药物的开发。

竞争格局和骨质疏松症药物市场份额分析

骨质疏松药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、沙特阿拉伯业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对骨质疏松药物市场的关注有关。

沙特阿拉伯骨质疏松症药物市场的一些主要参与者包括礼来公司、诺华公司、安进公司、塔布克制药公司、SPIMACO、Hikma Pharmaceuticals PLC、辉瑞公司、默克公司、Apotex 公司、ABIOGEN PHARMA SpA、Sudair Pharma、tadawipharma、Fresenius SE & Co. KGaA、Hayat Pharmaceutical Industries Co. PLC 和 SAJA Pharmaceuticals 等。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

5 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PIPELINE ANALYSIS

6 REGULATIONS OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET

6.1 SUBMISSION

6.2 ASSESSMENT

7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, SUMMARY WRITE-UP

7.1 OVERVIEW

8 EPIDEMIOLOGY

8.1 EPIDEMIOLOGY - OSTEOPOROSIS

8.2 EPIDEMIOLOGY – RELATED INDICATIONS

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 RISE IN PREVALENCE OF OSTEOPOROSIS

9.1.2 RISE IN GERIATRIC POPULATION

9.2 RESTRAINTS

9.2.1 SIDE EFFECTS ASSOCIATED WITH OSTEOPOROSIS DRUGS

9.2.2 HIGH COST OF OSTEOPOROSIS TREATMENT

9.3 OPPORTUNITIES

9.3.1 GOVERNMENT INITIATIVES

9.3.2 RISE IN INCIDENCE OF SPORTS AND TRAUMA INJURIES

9.4 CHALLENGES

9.4.1 GAPS IN OSTEOPOROSIS PATIENT PATHWAY

10 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY TYPE

10.1 OVERVIEW

10.2 PRIMARY OSTEOPOROSIS

10.3 SECONDARY OSTEOPOROSIS

11 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS

11.1 OVERVIEW

11.2 BISPHOSPHONATES

11.2.1 ALENDRONATE

11.2.2 ZOLEDRONIC ACID

11.2.3 RISEDRONATE

11.2.4 IBANDRONATE

11.2.5 OTHERS

11.3 MONOCLONAL ANTIBODIES

11.3.1 DENOSUMAB

11.3.2 ROMOSOZUMAB

11.4 HORMONE THERAPY

11.4.1 PARATHYROID HORMONE (TERIPARATIDE)

11.4.2 ESTROGEN

11.4.2.1 CONJUGATED ESTROGENS

11.4.2.2 SELECTIVE ESTROGEN RECEPTOR MODULATORS

11.4.2.3 ESTERIFIED ESTROGENS

11.4.2.4 OTHERS

11.4.3 CALCITONIN

11.4.4 OTHERS

11.5 OTHERS

12 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS TYPE

12.1 OVERVIEW

12.2 BRANDED

12.3 GENERIC

13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 INJECTABLE

13.3 ORAL

13.3.1 TABLETS

13.3.2 CAPSULES

13.3.3 OTHERS

13.4 OTHERS

14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY GENDER

14.1 OVERVIEW

14.2 FEMALE

14.3 MALE

15 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY AGE GROUP

15.1 OVERVIEW

15.2 GERIATRICS

15.3 ADULTS

15.4 PEDIATRICS

16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.3 SPECIALTY CLINICS

16.4 HOMECARE

16.5 OTHERS

17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 DIRECT TENDER

17.3 RETAIL SALES

17.3.1 HOSPITAL PHARMACY.

17.3.2 ONLINE RETAIL CHANNELS.

17.3.3 OTHER PHARMACY STORES.

17.4 OTHERS.

18 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: SAUDI ARABIA

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 AMGEN INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 PRODUCT PORTFOLIO

20.1.4 RECENT DEVELOPMENT

20.1.4.1 PRODUCT LAUNCH

20.2 ELI LILLY AND COMPANY

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 PRODUCT PORTFOLIO

20.2.4 RECENT DEVELOPMENT

20.3 HIKMA PHARMACEUTICALS PLC

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENT

20.3.4.1 ACQUISITION

20.4 NOVARTIS AG

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 PRODUCT PORTFOLIO

20.4.4 RECENT DEVELOPMENT

20.4.4.1 ACQUISITION

20.5 PFIZER INC.

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 PRODUCT PORTFOLIO

20.5.4 RECENT DEVELOPMENT

20.6 ABIOGEN PHARMA S.P.A

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.6.3.1 PRODUCT LAUNCH

20.7 APOTEX INC.

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.7.3.1 PRODUCT LAUNCH

20.8 FRESENIUS SE & CO. KGAA

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.8.4.1 INITIATION OF PHASE 3 TRIALS

20.9 HAYAT PHARMACEUTICAL INDUSTRIES CO. PLC

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENT

20.9.3.1 NEW PRODUCT LAUNCH

20.1 MERCK KGAA

20.10.1 COMPANY SNAPSHOT

20.10.2 REVENUE ANALYSIS

20.10.3 PRODUCT PORTFOLIO

20.10.4 RECENT DEVELOPMENT

20.11 SAJA PHARMACEUTICLAS

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENT

20.12 SPIMACO

20.12.1 COMPANY SNAPSHOT

20.12.2 REVENUE ANALYSIS

20.12.3 PRODUCT PORTFOLIO

20.12.4 RECENT DEVELOPMENT

20.13 SUDAIR PHARMA

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.13.3.1 ACQUISITION

20.14 TABUK PHARMACEUTICALS

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.14.3.1 ACQUISITION

20.15 TADAWIPHARMA

20.15.1 COMPANY SNAPSHOT

20.15.2 PRODUCT PORTFOLIO

20.15.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

表格列表

TABLE 1 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PIPELINE ANALYSIS

TABLE 2 PROJECTED NUMBER OF OSTEOPOROSIS PATIENTS, BY COUNTRY, 2021-2026, (IN UNITS)

TABLE 3 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, DIAGNOSIS RATE, 2021-2026, (IN %)

TABLE 4 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, TREATMENT RATE, 2021-2026, (IN %)

TABLE 5 COST ESTIMATION OF PATIENTS WITH OSTEOPOROSIS

TABLE 6 ESTIMATED COST OF MEDICATIONS FOR THE TREATMENT OF OSTEOPOROSIS

TABLE 7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 9 SAUDI ARABIA BISPHOSPHONATES IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 10 SAUDI ARABIA MONOCLONAL ANTIBODIES IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 11 SAUDI ARABIA HORMONE THERAPY IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 12 SAUDI ARABIA ESTROGEN IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)

TABLE 14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 15 SAUDI ARABIA ORAL IN OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 18 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 19 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 20 SAUDI ARABIA RETAIL SALES IN OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: SEGMENTATION

FIGURE 2 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DROC ANALYSIS

FIGURE 4 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: SEGMENTATION

FIGURE 11 RISE IN PREVALENCE OF OSTEOPOROSIS AND GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 PRIMARY OSTEOPOROSIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET IN 2022 & 2029

FIGURE 13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PREVALENCE RATE AGED BETWEEN 50-79 YEARS, 2020

FIGURE 14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PROJECTED NUMBER OF OSTEOPOROSIS PATIENTS, (2021-2026)

FIGURE 15 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, DIAGNOSIS RATE, (2020-2026)

FIGURE 16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, TREATMENT RATE, (2020-2026)

FIGURE 17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, ADHERENCE RATE

FIGURE 18 OSTEOPOROSIS RELATED INDICATIONS, SAUDI ARABIA, 2020

FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET

FIGURE 20 ANNUAL FEMUR FRACTURE RATE IN SAUDI ARABIAN POPULATION, PER 1,000,000 PERSONS-YEARS

FIGURE 21 OSTEOPOROSIS PATIENT JOURNEY IN KINGDOM OF SAUDI ARABIA

FIGURE 22 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, 2021

FIGURE 23 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 24 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 25 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 26 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, 2021

FIGURE 27 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION)

FIGURE 28 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, CAGR (2022-2029)

FIGURE 29 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 30 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, 2021

FIGURE 31 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, 2022-2029 (USD MILLION)

FIGURE 32 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, CAGR (2022-2029)

FIGURE 33 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE

FIGURE 34 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 35 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 36 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 37 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 38 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, 2021

FIGURE 39 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, 2022-2029 (USD MILLION)

FIGURE 40 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, CAGR (2022-2029)

FIGURE 41 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 42 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, 2021

FIGURE 43 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)

FIGURE 44 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, CAGR (2022-2029)

FIGURE 45 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 46 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, 2021

FIGURE 47 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 48 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 49 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 50 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 51 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 52 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 53 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 54 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Saudi Arabia Osteoporosis Drugs Market will be projected to grow at a CAGR of 2.9% during the forecast by 2029.
The side effects associated with osteoporosis drugs and high treatment cost are poised to restrict the growth of Saudi Arabia Osteoporosis Drugs Market.
Eli Lilly and Company (U.S.), Novartis AG (Switzerland) , Amgen Inc. (U.S.), Tabuk pharmaceuticals (Saudi Arabia), SPIMACO (Saudi Arabia), Hikma Pharmaceuticals PLC (Jordan), Pfizer Inc. (U.S.) , Merck KGaA (Germany) , Apotex Inc. (Canada), ABIOGEN PHARMA S.p.A. (Italy), Sudair Pharma (Saudi Arabia), tadawipharma. (Saudi Arabia), Fresenius SE & Co. KGaA (Germany), Hayat Pharmaceutical Industries Co. PLC (Jordan), and SAJA Pharmaceuticals (Saudi Arabia) are the major players operating in the Saudi Arabia Osteoporosis Drugs Market.
Rise in Prevalence of Osteoporosis, and Rise in geriatric population are the significant factors flourishing the growth of the Saudi Arabia Osteoporosis Drugs Market.